# A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence

> **NCT05674045** · PHASE2 · COMPLETED · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 51 (actual)

## Conditions studied

- Stress Urinary Incontinence

## Interventions

- **DRUG:** EG017 3mg
- **DRUG:** EG017 6mg

## Key facts

- **NCT ID:** NCT05674045
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-06
- **Primary completion:** 2022-01-06
- **Final completion:** 2022-09-26
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2023-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05674045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05674045, "A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05674045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*